Omnicell (OMCL) Q2 FY26 earnings call

Omnicell delivered strong Q2 FY26 financial results, particularly in profitability, driven by disciplined execution and a one-time tariff refund. While the company sees robust pipeline activity and increasing customer engagement for its new Titan XT and OmniSphere platforms, purchasing decisions are taking longer, leading to a wider full-year product bookings guidance range. Management remains confident in the long-term opportunity and its competitive positioning in the evolving healthcare technology landscape.